Ajou University Medical Center (AUMC) Tuesday held a kickoff event with Syapse, a medical platform using real-world data, to lay the foundation for cancer precision medicine.
The hospital signed a business agreement with Syapse on Jan. 9 to build a cancer precision medical platform.
|Ajou University Medical Center has begun to build a medical platform for cancer precision medicine by partnering with Syapse. (AUMC)|
The two institutions will conduct research and develop promotion plans to spread the platform and play a role in spreading the data-sharing network in detail.
They also began to cooperate to support research and development of expanded function and improvement of the domestic precision medical platform, promote new strategic plans, and host an international academic symposium, the hospital said.
“We expect our cooperation will produce various results,” said Kim Se-hyuk, director of the hospital’s Cancer Center.
The desired results Kim cited are quality treatment, research, data management, and capacity enhancement through stabilization of OCS/EMR, the establishment of structured order communication system (OCS) and electronic medical record (EMR), sharing data through establishment of a global cooperative system between hospitals, and providing information that integrates clinical data and genomic data.
The hospital will create an optimal environment for domestic cancer patients to receive customized diagnosis and treatment based on the latest global standards, Kim said.
Syapse has partnered with leading hospitals, global pharmaceuticals, and regulators to improve therapy for cancer patients by forming one of the world’s largest networks that use the world’s real-world evidence.
Syapse Learning Health Network is a network of global hospitals that share real-world data in need of diagnosis and promote cooperation among hospitals.
The platform allows medical teams, including doctors and nurses, too see which cancer treatment has produced the best results in patients with similar clinical characteristics and genomes.
All the collaborations are done through standardized and de-identified data platforms, and the institutions comply with the regulations on privacy.
“We expect to improve the quality of cancer therapy and contribute to the mid- to the long-term development of domestic precision medicine,” AUMC Director Han Sang-uk said.
<© Korea Biomedical Review, All rights reserved.>